Consistent with the oncogenic role of METTL3 in AML,41, 42, 43 treatment of mouse and human AML cells with STM2457 consistently demonstrates growth reduction, myeloid differentiation, and cell cycle arrest.153. This evidence concerns the gene METTL3 and acute myeloid leukemia.